Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/2/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Lifecore Biomedical (LFCR) PT Raised to $6 at Stephens
October 7, 2024 9:19 AM EDTStephens analyst Jacob Johnson raised the price target on Lifecore Biomedical (NASDAQ: LFCR) to $6.00 (from $5.00) while maintaining a Equal Weight rating.
The analyst comments "LFCR posted 1Q25 revenue/gross margins that came in ahead of us and consensus estimates. Elevated OpEx... More
Stephens Reiterates Equal Weight Rating on Lifecore Biomedical (LFCR)
October 4, 2024 1:16 PM EDTStephens analyst Jacob Johnson reiterated an Equal Weight rating and $5.00 price target on Lifecore Biomedical (NASDAQ: LFCR).
The analyst comments "LFCR reported a 1Q25 revenue beat vs. us/consensus which flowed through to better than expected gross margins, while adj. EBITDA came in below... More
